CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 15 enrolled
Drug / intervention
adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02904902
NCT02904902Phase 3Completed
CompareCT.gov

A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa

AbbVie·interventional·Posted Sep 19, 2016·Updated May 12, 2020

In Brief

A Phase 3 clinical trial evaluating adalimumab for Hidradenitis Suppurativa. Completed, enrolled 15 participants across 8 sites.

Detailed Summary

This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 19, 2016
Enrollment StartSep 6, 2016
Primary CompletionSep 1, 2017
Study CompletionMay 30, 2019
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 9.8 years ago

Interventions

adalimumabdrug

Subcutaneous Injection